2013-03-13 21:03:51 -
Phase IIa data to be Presented at the 65(th) Annual Meeting of the American
Academy of Neurology
South San Francisco, CA, March 13, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that an Emerging Science Session poster presentation
relating to tirasemtiv is scheduled to be presented at the 65(th) Annual Meeting
of the American Academy of Neurology to be held March 16-23, 2013 at the San
Diego Convention Center in San Diego, CA.
Tirasemtiv is the lead drug candidate that has emerged from the company's
skeletal muscle contractility program. Tirasemtiv selectively activates the
fast skeletal muscle troponin complex by increasing its sensitivity to calcium,
which increases skeletal muscle force in response to neuronal input and delays
the onset and reduces the degree of muscle fatigue. Tirasemtiv is currently
being evaluated in BENEFIT-ALS, an international, double-blind, randomized,
placebo-controlled, Phase IIb clinical trial designed to evaluate the safety,
tolerability and potential efficacy of this novel drug candidate in patients
with amyotrophic lateral sclerosis.
Emerging Science Presentation at the 65(th) Annual Meeting of the American
Academy of Neurology
Title: A Study to Evaluate Efficacy, Safety and Tolerability of Single Doses of
Tirasemtiv in Patients with Myasthenia
Gravis
Presenter: Donald B. Sanders, MD, FAAN, Professor, Division of Neurology and
Founder of the Duke Myasthenia Gravis Clinic and Chair
Date: Wednesday, March 20, 2013
Session: 5LB.001 - Emerging Science Session
Presentation and Poster Number: 009
Presentation Time: 6:09 PM (Pacific Time)
Poster on Display: 5:45 PM - 7:00 PM (Pacific Time)
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the
discovery and development of novel small molecule therapeutics that modulate
muscle function for the potential treatment of serious diseases and medical
conditions. Cytokinetics' lead drug candidate from its cardiac muscle
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment of heart failure. Amgen Inc. holds an exclusive
license worldwide (excluding Japan) to develop and commercialize omecamtiv
mecarbil and related compounds, subject to Cytokinetics' specified development
and commercialization participation rights. Cytokinetics is independently
developing tirasemtiv, a skeletal muscle activator, as a potential treatment for
diseases and conditions associated with aging, muscle wasting or neuromuscular
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status by
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines Agency for the potential treatment of amyotrophic
lateral sclerosis, a debilitating disease of neuromuscular impairment in which
treatment with tirasemtiv produced potentially clinically relevant
pharmacodynamic effects in Phase II trials. All of these drug candidates have
arisen from Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex biological
infrastructure that plays a fundamental role within every human cell. Additional
information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the
Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics
disclaims any intent or obligation to update these forward-looking statements,
and claims the protection of the Act's safe harbor for forward-looking
statements. Examples of such statements include, but are not limited to,
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates. Such
statements are based on management's current expectations, but actual results
may differ materially due to various risks and uncertainties, including, but not
limited to, potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates and
potential drug candidates that could slow or prevent clinical development or
product approval, including risks that current and past results of clinical
trials or preclinical studies may not be indicative of future clinical trials
results and that Cytokinetics' drug candidates and potential drug candidates may
have unexpected adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to Cytokinetics'
business, investors should consult Cytokinetics' filings with the Securities and
Exchange Commission.
Contact:
Joanna (Jodi) L. Goldstein
Manager, Corporate Communications & Marketing
(650) 624-3000
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Cytokinetics, Inc. via Thomson Reuters ONE
[HUG#1685169]
